

REMARKS/ARGUMENTS

Claims 1-12 are canceled.

Claims 13-31 are new.

Support for each new claim is found throughout the originally filed specification and at the originally filed claims.

Upon entry of the amendment, Claims 13-31 will be active.

No new matter is believed to have been added.

Applicants thank Examiner McKelvey for indicating, in the conversation of September 20, 2006, that an RCE could be filed wherein the composition claims were canceled and new method claims submitted.

The 35 U.S.C. 102(b) rejection of claims 1-2 is obviated by cancellation of these claims.

Applicants have canceled all composition claims and, in their place, submitted method claims.

Applicants note that an error was made in the Response to the Official Action of November 30, 2005, filed on March 27, 2006. The inventor's declaration, and Remarks section, argued that administration of the claimed composition to rats resulted in a different blood pressure response (i.e., did not lower blood pressure) than the response obtained by administering the composition of JP 2000-157226 A to rats (i.e., lowered blood pressure).

Applicants now submit this to be incorrect.

When the data given in the inventor's declaration was collected, Wister Rats were used as the test animals. Wister Rats usually have normal blood pressure readings. Conversely, when the composition of, for example, JP 2000-157226 A was tested in rats, Spontaneously Hypertensive Rats (SHR) were utilized.

Application Serial No. 10/771,527  
Response to Official Action of July 17, 2006

Applicants have now conducted further tests on the composition of the instant invention and found that in SHR, the composition of the instant invention does, in fact, decrease blood pressure. Accordingly, the composition of the instant invention and the composition of, for example JP 2000-157226 A, appear to be the same with respect to decreasing high blood pressure in SHR.

Applicants submit that the method claims of the instant invention are allowable over the cited art because the conditions treated in the method claims are not described or suggested in the cited art.

Applicants submit the application is currently in condition for allowance. Early notification to this effect is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.  
Norman F. Oblon

  
Charles J. Andres Jr., Ph.D.  
Attorney of Record  
Registration No. 57,537

Customer Number  
**22850**

Tel: (703) 413-3000  
Fax: (703) 413 -2220  
(OSMMN 06/04)